Malaria in children - prevention and management

Infectious Disorders - Drug Targets

Volumn 13, Issue 4, 2013, Pages 303-311

  Dramowski, Angela ^a   Frigati, Lisa ^a   Rabie, Helena ^a   Cotton, Mark ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Artesunate; Children; Malaria; Malaria prevention; Malaria treatment; Plasmodium

Indexed keywords

AMODIAQUINE; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ARTESUNATE; ARTESUNATE PLUS PYRONARIDINE; ATOVAQUONE PLUS PROGUANIL; CHLOROQUINE; CLINDAMYCIN; DIHYDROARTEMISININ PLUS PIPERAQUINE; DOXYCYCLINE; MALARIA VACCINE; MEFLOQUINE; PRIMAQUINE; QUININE;

BED NET; CHILD; CHILDHOOD MORTALITY; CLINICAL TRIAL (TOPIC); DISEASE TRANSMISSION; HUMAN; INDOOR RESIDUAL SPRAYING; MALARIA; MALARIA FALCIPARUM; MALARIA RAPID TEST; MICROSCOPY; MULTIPLE ORGAN FAILURE; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; WORLD HEALTH ORGANIZATION;

ANTIMALARIALS; CHILD; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG RESISTANCE; HUMANS; MALARIA;

EID: 84893467573     PISSN: 18715265     EISSN: 18755852     Source Type: Journal    
DOI: 10.2174/1871526513666131129154446     Document Type: Review

References (58)

1. World Health Organisation. World malaria report 2011. Available at: http://www. who. int/malaria/publications/atoz/9789241564403/en/i ndex. html (Accessed August 22, 2012).
2. Carrara, V. I.; Sirilak, S.; Thonglairua, M. J.; Rojanawatsirivet, C.; Proux, S.; Gilbo, S. V.; Brockma, N. A.; Ashley, E. A.; McGready, R.; Krudsood, S.; Leemingsawat, S.; Looareesuwa, N. S.; Singhasivano, N. P.; White, N.; Nosten, F. Deployment of early diagnosis and mefloquine-artesunate treatment of falciparum malaria in Thailand: the Tak Malaria Initiative. PLo. S. Med., 2006, 3(6), e183.
3. Kleinschmidt, I.; Schwabe, C.; Benavente, L.; Torrez, M.; Ridl, F. C.; Segura, J. L.; Ehmer, P.; Nchama, G. N.; Marked increase in child survival after four years of intensive malaria control. Am. J. Trop. Med. Hyg., 2009, 80 (6), 882-888.
4. Price, R. N.; Douglas, N. M.; Anstey, N. M. New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance. Curr. Opin. Infect. Dis., 2009, 22, 430-435.
5. Cox-Singh, J.; Davis, T. M.; Lee, K. S.; Shamsul, S. S.; Matusop, A.; Ratnam, S.; Rahman, H. A.; Conway, D. J.; Singh, B. Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening. Clin. Infect. Dis., 2008, 46(2), 165-171.
6. Imwong, M.; Nakeesathit, S.; Day, N. P. T.; White, N. J. A review of mixed malaria species infections in anopheline mosquitoes. Malaria J., 2011, 10, 253. Available at: http://www. malariajournal. com/content/10/1/253 (Accessed August 23, 2012).
7. Bruce, M. C.; Macheso, A.; Kelly-Hope, L. A.; Nkhoma, S.; McConnachie, A.; Molyneux, M. E. Effect of transmission setting and mixed species infections on clinical measures of malaria in malawi. PLoS One, 2008, 3(7), e2775.
8. Marques, P. X.; Saúte, F.; Pinto, V. V, Cardoso, S.; Pinto, J.; Alonso, P. L.; Rosário, V. E.; Arez, A. P. Plasmodium species mixed infections in two areas of manhiça district, mozambique. Int. J. Biol. Sci., 2005, 1(3), 96-102.
9. Mboera, L. E.; Kamugisha, M. L.; Rumisha, S. F.; Msangeni, H. A.; Barongo, V.; Molteni, E.; Kitua, A. Y. The relationship between malaria parasitaemia and availability of healthcare facility in Mpwapwa district, central Tanzania. Tanzan Health Res. Bull., 2006, 8(1), 22-27.
10. Malaria Atlas Project (MAP). Available at: http://www. map. ox. ac. uk/browse-resources/endemicity/Pf_class/world/(Accessed August 29, 2012).
11. Fischer, P. R. Malaria and newborns. J. Trop. Pediatr., 2003, 49, 132-134.
12. Mungai, M.; Tegtmeier, G.; Chamberland, M.; Parise, M. Transfusion transmitted malaria in the United States from 1963 through 1999. N. Engl. J. Med., 2001, 344, 1973-1978.
13. World Health Organisation. Guidelines for the treatment of malaria-second edition (2010). Available at: http://whqlibdoc. who. int/publications/2010/9789241547925_eng. pdf (Accessed August 29, 2012).
14. Berkley, J. A.; Bejon, P.; Mwangi, T.; Gwer, S.; Maitland, K.; Williams, T. N.; Mohammed, S.; Osier, F.; Kinyanjui, S.; Fegan G, Lowe, B. S.; English, M.; Peshu, N.; Marsh, K.; Newton, C. R. HIV infection malnutrition and invasive bacterial infection among children with severe malaria. Clin. Infect. Dis., 2009, 49, 336-343.
15. Bassat, Q.; Guinovart, C.; Sigaúque, B.; Mandomando, I.; Aide, P.; Sacarlal, J.; Nhampossa, T.; Bardají, A.; Morais, L.; Machevo, S.; Letang, E.; Macete, E.; Aponte, J. J.; Roca, A.; Menéndez, C.; Alonso, P. L. Severe malaria and concomitant bacteraemia in children admitted to a rural Mozambican hospital. Trop. Med Int. Health, 2009, 14, 1011-1019.
16. Barnett, E. D. In: Textbook of Pediatric Infectious Diseases. Feigin R. D., Cherry J. D., Ed. W. B. Saunders. V; Philadelphia, 2009, 6, pp. 2899-2920.
17. Chandramohan, D.; Jaffar, S.; Greenwood, B. Use of clinical algorithms for diagnosing malaria. Trop. Med. Int. Health, 2002, 7, 45-52.
18. Vinnemeier, C. D.; Schwarz, N. G.; Sarpong, N.; Loag, W.; Acquah, S.; Nkrumah, B.; Huenger, F.; Adu-sarkodie, Y.; May, J. Predictive value of fever and palmar pallor for P. falciparum parasitaemia in children from an endemic area. PLoS One, 2012, 7, e36678.
19. Abba, K., Deeks, J. J.; Olliaro, P. L.; Naing, C. M.; Jackson, S. M.; Takwoingi, Y.; Donegan, S.; Garner, P. Rapid diagnostic tests for diagnosing uncomplicated P. falciparum malaria in endemic countries. Cochrane Db. Syst. Rev. S., 2011, 7.
20. Mubi, M.; Janson, A.; Warsame, M.; Mårtensson, A.; Källander, K.; Petzold, M. G.; Ngasala, B.; Maganga, G.; Gustafsson, L. L.; Massele, A.; Tomson, G.; Premji, Z.; Björkman, A. Malaria rapid testing by community health workers is effective and safe for targeting malaria treatment: Randomised cross-over trial in Tanzania. PLoS. ONE, 2011, 6(7).
21. Luchavez, J.; Baker, J.; Alcantara, S.; Belizario, V. J.; Cheng, Q.; Mccarthy, J. S.; Bell, D. Laboratory demonstration of a prozonelike effect in HRP2-detecting malaria rapid diagnostic tests: implications for clinical management. Malaria J., 2011, 10, 286.
22. Koita, O. A.; Doumbo, O. K.; Ouattara, A.; Tall, L. K.; Konaré, A.; Diakité, M.; Diallo, M.; Sagara, I.; Masinde, G. L.; Doumbo, S. N.; Dolo, A.; Tounkara, A.; Traoré, I.; Krogstad, D. J. False-negative rapid diagnostic tests for malaria and deletion of the histidine-rich repeat region of the hrp2 gene. Am. J. Trop. Med. Hyg., 2012, 86(2), 194-198.
23. Ramutton, T.; Hendriksen, I. C.; Mwanga-Amumpaire, J.; Mtove, G.; Olaosebikan, R.; Tshefu, A. K.; Onyamboko, M. A.; Karema, C.; Maitland, K.; Gomes, E.; Gesase, S.; Reyburn, H.; Silamut, K.; Chotivanich, K.; Promnares, K.; Fanello, C. I.; Von, S. L.; Day, N. P.; White, N. J.; Dondorp, A. M.; Imwong, M.; Woodrow, C. J. Sequence variation does not confound the measurement of plasma PfHRP2 concentration in African children presenting with severe malaria. Malaria J., 2012, 11, 276.
24. Berkley, J. A.; Ross, A.; Mwangi, I.; Osier, F. H.; Mohammed, M.; Shebbe M.; Lowe B. S.; Marsh K, Newton C. R. Prognostic indicators of early and late death in children admitted to district hospital in Kenya: cohort study. BMJ., 2003, 326, 361.
25. Von, S. L.; Olaosebikan, R.; Hendriksen, I. C. Predicting the clinical outcome of severe falciparum malaria in African children: findings from a large randomized trial. Clin. Infect. Dis., 2012, 54, 1080-1090.
26. Crawley, J.; Waruiru, C.; Mithwani, S.; Mwangi, I.; Watkins, W.; Ouma, D.; Winstanley, P.; Peto, T.; Marsh, K. Effect of phenobarbital on seizure frequency and mortality in childhood cerebral malaria: a randomised, controlled intervention study. Lancet, 2000, 355, 701-706.
27. Meremikwu, M.; Marson, A. G. Routine anticonvulsants for treating cerebral malaria. Cochrane Db. Syst. Rev. S., 2002, 2.
28. Namutangula, B.; Ndeezi, G.; Byarugaba, J. S.; Tumwine, J. K. Mannitol as adjunct therapy for childhood cerebral malaria in Uganda: a randomized clinical trial. Malaria J., 2007, 6, 138.
29. Maitland, K.; Kiguli, S.; Opoka, R. O.; et al. Mortality after fluid bolus in African children with severe infection. N. Engl. J. Med., 2011, 364, 2483-2495.
30. Van, G. P. J.; Hesselink, D. A.; Bezemer, J. M.; Wismans, P. J.; Overbosch, D. Efficacy and safety of exchange transfusion as an adjunct therapy for severe Plasmodium falciparum malaria in nonimmune travelers: a 10-year single-center experience with a standardized treatment protocol. Transfusion, 2010, 50(4), 787-794.
31. Dondorp, A.; Nosten, F.; Stepniewska, K.; Day, N.; White, N. J. For the Southeast Asian quinine artesunate malaria trial (SEAQUAMAT) group. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet, 2005, 366, 717-725.
32. Dondorp, A. M.; Fanello, C. I.; Hendriksen, I. C.; et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet, 2010, 376(9753), 1647-1657.
33. Mithwani, S.; Aarons, L.; Kokwaro, G. O.; Majid, O.; Muchohi, S.; Edwards, G.; Mohamed, S.; Marsh, K.; Watkins, W. Population pharmacokinetics of artemether and dihydroartemisinin following single intramuscular dosing of artemether in African children with severe falciparum malaria. Br. J. Clin. Pharmacol., 2004, 57, 146-152.
34. Aceng, J. R.; Byarugaba, J. S.; Tumwine, J. K. Rectal artemether versus intravenous quinine for the treatment of cerebral malaria in children in Uganda: randomised clinical trial. BMJ., 2005, 330(7487), 334.
35. Gargano, N.; Cencil, F.; Bassat, Q. Antimalarial efficacy of piperaquine-based antimalarial combination therapies: facts and uncertainties. Trop. Med. Int. Health, 2011, 12, 1466-1473.
36. Nambozi, M.; Van, G. J. P.; Hachizovu, S.; Chaponda, M.; Mukwamataba, D.; Mulenga, M.; Ubben, D.; D'Alessandro, U. Safety and efficacy of dihydroartemisininpiperaquine versus artemetherlumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children. Malaria J., 2011, 10, 50.
37. Duparc, S.; Borghini-Fuhrer, I.; Craft, C. J.; Arbe-Barnes, S.; Miller, R. M.; Shin, C. S.; Fleckenstein, L. Safety and efficacy of pyronaridine-artesunate in uncomplicated acute malaria: an integrated analysis of individual patient data from six randomized clinical trials. Malaria J., 2013, 12, 70.
38. Lombard, M. C.; N'Da, D. D.; Van Ba, T. C.; Wein, S.; Norman, J.; Wiesner, L.; Vial, H. Potent in vivo anti-malarial activity and representative snapshot pharmacokinetic evaluation of artemisininquinoline hybrids. Malaria J., 2013, 12(1), 71.
39. Barnes, K. I.; Little, F.; Smith, P. J.; Evans, A.; Watkins, W. M.; White, N. J. Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. Clin. Pharmacol. Ther., 2006, 80, 582-596.
40. Price, R. N.; Hasugian, A. R.; Ratcliff, A.; Siswantoro, H.; Purba, H. L.; Kenangalem, E.; Lindegardh, N.; Penttinen, P.; Laihad, F.; Ebsworth, E. P.; Anstey, N. M.; Tjitra, E. Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria. Antimicrob. Agents Ch., 2007, 51, 4090-4097.
41. Barnes, K. I.; Watkins, W. M.; White, N. J. Antimalarial dosing regimens and drug resistance. Trends Parasitol., 2008, 24, 127-134.
42. Ikilezi, G.; Achan, J.; Kakuru, A.; Ruel, T.; Charlebois, E.; Clark, T. D.; Rosenthal, P. J.; Havlir, D.; Kamya, M. R.; Dorsey, G. Prevalence of asymptomatic parasitemia and gametocytemia among HIV-infected ugandan children randomized to receive different antiretroviral therapies. Am. J. Trop. Med. Hyg., 2013, 88(4), 744-746.
43. Newton, P. N.; Fernandez, F. M.; Plancon, A.; et al. A collaborative epidemiological investigation into the criminal fake artesunate trade in Southeast Asia. PLoS. Med., 2008, 5, e32.
44. Nayyar, G. M.; Breman, J. G.; Newton, P. N.; Herrington, J. Poorquality antimalarial drugs in southeast Asia and sub-Saharan Africa. Lancet Infect. Dis., 2012, 12(6), 488-496.
45. Worldwide Antimalarial Resistance Network (WWARN). Malaria: Drug Resistance Maps [online]. http://www. wwarn. org/resistance (Accessed March 20, 2013).
46. Dondorp, A. M.; Nosten, F.; Yi, P.; et al. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med., 2009, 361, 455-467.
47. Dondorp, A. M.; Yeung, S.; White, L.; et al. Artemisinin resistance: current status and scenarios for containment. Nat. Rev. Micro., 2010, 8, 272-280.
48. Phyo, A. P.; Nkhoma, S.; Stepniewska, K. et al. Emergence of artemisinin-resistant malaria on the Western border of Thailand: a longitudinal study. Lancet, 2012, 379, 1960-1966.
49. Greenwood, B. Intermittent preventive treatment-a new approach to the prevention of malaria in children in areas with seasonal malaria transmission. Trop. Med. Int. Health, 2006, 11, 983-991.
50. Meremikwu, M. M.; Donegan, S.; Sinclair, D.; Esu, E.; Oringanje, C. Intermittent preventive treatment for malaria in children living in areas with seasonal transmission. Cochrane Db. Syst. Rev. S.; 2012, 2, CD003756.
51. Wilson, A. L. on behalf of the IPTc Taskforce. A systematic review and meta-analysis of the efficacy and safety of intermittent preventive treatment of malaria in children (IPTc). PLoS ONE, 2011, 6(2), e16976.
52. World Health Organisation. World malaria report. 2011. Available at: http://www. who. int/malaria/world_malaria_report_2011/WMR201 1_noprofiles_lowres. pdf (Accessed March 20, 2013).
53. World Health Organisation. Indoor residual spraying: use of indoor residual spraying for scaling up global malaria control and elimination. 2006. http://www. who. int/malaria/publications/atoz/htm_mal_2006_1112/en/index. html (Accessed August 28, 2012).
54. Greenwood, B.; Targett, G. Do we still need a malaria vaccine? Parasite Immunol., 2009, 31, 582-586.
55. Butler, D. Initiative targets malaria eradication. Nature, 2009, 462, 19.
56. Saul, A.; Fay, M. P. Human immunity and the design of multicomponent, single target vaccines. PLoS. One, 2007, 2, e850.
57. The RTS.; S Clinical Trials Partnership. First results of phase 3 trial of RTS.; S/AS01 malaria vaccine in African children. N. Engl. J. Med., 2011, 365(20), 1863-1875.
58. The RTS.; S Clinical Trials Partnership. A Phase 3 Trial of RTS; S/AS01 malaria vaccine in african infants. N. Engl. J. Med., 2012, 367, 2284-2295.